Bone Abstracts

High doses of BMPs are needed to achieve clinical success in bone fracture repair with currently available devices. BMP6 has a higher potency in stimulation of bone formation then its paralogue BMP7 due to less susceptibility to Noggin. The BMP6 carrier is a whole blood derived coagulum (WBCD) from the peripheral blood (OSTEOGROW). This WBCD, as an endogenous biocompatible material, significantly reduces the inflammatory response associated with current BMP-based treatments. M...

Bone morphogenetic protein 6 (BMP6) is a member of TGF-β superfamily with a high potential to induce new bone and cartilage. Here we demonstrate that BMP6 compared to the BMP7 paralog has unique biological properties. Previously, we showed that BMP6 is more active at lower amounts then BMP7 because of increased resistance to noggin due to lysine in position 60. Next, we discovered that BMP6 binds to blood coagulum components, which when modified with calcium salt and a fi...

BMP6 is a member of the TGFβ superfamily with a high potential to induce new bone formation. Recently, we discovered that blood coagulum from the patient’s own blood (WBCD) modified with calcium salts serves as an appropriate autologous carrier for BMPs (OSTEOGROW device). Preclinical experiments indicate that BMP6 is efficacious when used in a significantly lower amounts than BMP2 and BMP7. Besides testing its osteogenic activity, we also tested the influence of the...